{
    "title": "112_hr6638",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Supporting Access to Formulated and \nEffective Compounded Drugs Act of 2012'' or the ``S.A.F.E. Compounded \nDrugs Act of 2012''.\n\nSEC. 2. ENHANCED REQUIREMENTS FOR COMPOUNDED DRUGS.\n\n    (a) In General.--Section 503A of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 353a) is amended--\n            (1) in subsection (a)(1)(A), by inserting ``that is \n        registered with the Secretary under subsection (b)(6) (or is \n        subject to the exception under subsection (b)(6)(C))'' after \n        ``State licensed pharmacy'';\n            (2) in subsection (b)--\n                    (A) in paragraph (1)(D), by striking ``regularly or \n                in inordinate amounts (as defined by the Secretary)''; \n                and\n                    (B) by adding at the end the following:\n            ``(4) Notification.--\n                    ``(A) Prescriber notification.--Before providing a \n                prescription order for a drug to be compounded under \n                subsection (a), the physician or other licensed \n                practitioner who will write such order shall--\n                            ``(i) inform the individual patient for \n                        whom such order is being written that a \n                        compounded drug is being prescribed; and\n                            ``(ii) provide such patient with a written \n                        document containing information concerning the \n                        availability, safety, and production of \n                        compounded drugs.\n                    ``(B) Confirmation by pharmacist.--Except in the \n                case of a compounded drug product used in a procedure \n                described in subparagraph (C), a licensed pharmacist or \n                licensed physician who dispenses a compounded drug \n                under subsection (a) shall, at the time such drug is \n                dispensed--\n                            ``(i) confirm that the patient (or the \n                        individual to whom the drug is delivered on \n                        behalf of the patient) understands that the \n                        drug is a compounded drug; and\n                            ``(ii) provide a written document \n                        containing the information described in \n                        subparagraph (A)(ii).\n                    ``(C) Provider notification.--Prior to providing a \n                health care service that will be conducted by a health \n                care provider in a health care setting (such as a \n                hospital or a physician's office) and during which \n                service a drug compounded under subsection (a) will be \n                administered to a patient for purposes of treating such \n                patient, the health care provider shall--\n                            ``(i) inform the patient that a compounded \n                        drug will be used during the procedure; and\n                            ``(ii) provide such patient with a written \n                        document containing the information described \n                        in subparagraph (A)(ii).\n            ``(5) Labeling.--\n                    ``(A) In general.--A drug product compounded under \n                subsection (a) shall be clearly labeled as a `non-FDA \n                approved compounded drug product'.\n                    ``(B) Development of requirements.--In determining \n                the requirements for the label under subparagraph (A), \n                the Secretary--\n                            ``(i) shall establish, and consult with, a \n                        temporary advisory committee on compounded drug \n                        product labeling requirements; and\n                            ``(ii) may establish different labeling \n                        requirements for--\n                                    ``(I) a compounded drug product \n                                intended for use by a health care \n                                provider in an office or treatment \n                                setting; and\n                                    ``(II) a compounded drug product \n                                intended for any use not described in \n                                subclause (I).\n            ``(6) Registration.--\n                    ``(A) Establishment of process.--The Secretary, in \n                consultation with experts and representatives of \n                stakeholders including pharmacies, compounding \n                pharmacies, State regulators, and health care \n                providers, shall establish a process for pharmacies \n                described in subsection (a)(1)(A) to register as a \n                compounding pharmacy. Such registration shall be \n                conducted through an electronic method.\n                    ``(B) Registration requirement.--Except as provided \n                in subparagraph (C), in order to be registered with the \n                Secretary for purposes of subsection (a)(1)(A), every \n                person who owns or operates a pharmacy shall submit to \n                the Secretary, in such time and manner as the Secretary \n                may require--\n                            ``(i) contact information for the pharmacy;\n                            ``(ii) the State or States that the \n                        pharmacy is licensed in;\n                            ``(iii) the methods used by the facility in \n                        compounding; and\n                            ``(iv) any additional information required \n                        by the Secretary, which may include the \n                        quantity of product compounded at such pharmacy \n                        for the purpose of determining if a drug \n                        manufacturing facility is inappropriately \n                        registering as a compounding pharmacy.\n                    ``(C) Exception.--A pharmacy shall be exempt from \n                the requirement to register under subsection (a)(1)(A) \n                if the pharmacy--\n                            ``(i) employs fewer than 20 full-time \n                        employees (or 20 full-time equivalents); and\n                            ``(ii) performs traditional compounding of \n                        drug products for use in a single State.''; and\n            (3) by adding at the end the following:\n    ``(g) Database.--\n            ``(1) In general.--The Secretary shall establish and \n        maintain a database of information on pharmacies compounding \n        drug products under subsection (a) that are licensed in more \n        than one State, including--\n                    ``(A) the minimum standards for a compounding \n                pharmacy license in each State;\n                    ``(B) relevant information provided to the \n                Secretary by State agencies that regulate pharmacies; \n                and\n                    ``(C) other information determined relevant by the \n                Secretary.\n            ``(2) Design.--The database under paragraph (1)--\n                    ``(A) shall be accessible, as determined \n                appropriate by the Secretary, to State agencies that \n                regulate pharmacies that compound drug products;\n                    ``(B) shall enable States and the Secretary to \n                share information to ensure appropriate oversight of \n                pharmacies that compound drug products; and\n                    ``(C) shall be used by the Secretary to inform the \n                Federal inspection and oversight of pharmacies that \n                compound drug products to ensure that issues and \n                pharmacies identified in the database receive \n                appropriate oversight.\n    ``(h) Minimum Standards.--\n            ``(1) The Secretary shall establish minimum standards for \n        the safe production of compounded drug products.\n            ``(2) The Secretary shall determine these minimum standards \n        and shall determine the drug products that must meet the \n        minimum standards.\n            ``(3) The standards may include but is not limited to the \n        intended route of administration and if the drug is sterile or \n        non-sterile. If appropriate, the Secretary may consider the \n        different types of drug products and set appropriate minimum \n        standards for specific drug types or drug uses.\n    ``(i) Training.--The Secretary shall conduct a series of regional \ntraining opportunities for State agencies that regulate pharmacies that \ncompound drug products. These training opportunities should include \ninformation on the minimum standards discussed in (h), sample \ninspection protocol, and recordkeeping to facilitate the inclusion of \nState findings and inspections into the database discussed in (g).''.\n    (b) Deadlines and Advisory Committees.--\n            (1) Deadline for issuance of regulations.--Not later than \n        18 months after the date of enactment of this Act, the \n        Secretary of Health and Human Services shall issue regulations \n        to implement--\n                    (A) paragraphs (4) and (5) of section 503A(b) of \n                the Federal Food, Drug, and Cosmetic Act, as added by \n                subsection (a); and\n                    (B) subsection (g) of section 503A of such Act.\n            (2) Labeling advisory committee.--\n                    (A) Establishment.--The Secretary of Health and \n                Human Services shall establish an advisory committee on \n                labeling (as defined in section 201 of the Federal \n                Food, Drug, and Cosmetic Act (21 U.S.C. 321)) of \n                compounded drug products and shall consult such \n                committee in the development of the regulations under \n                paragraph (1)(A).\n                    (B) Membership.--The advisory committee shall \n                include representatives of patients or consumers, \n                health care providers, compounding pharmacies, State \n                agencies that regulate compounding pharmacies, and at \n                least one member with expertise on clearly \n                communicating information in such labeling of drugs.\n                    (C) Meetings.--The advisory committee shall hold an \n                initial meeting not later than 6 months after the date \n                of enactment of this Act.\n                    (D) Recommendations.--Not later than 12 months \n                after the date of enactment of this Act, the advisory \n                committee shall submit to the Secretary of Health and \n                Human Services recommendations on the regulations under \n                paragraph (1)(A), including recommendations on the type \n                of information and language that should be included on \n                the labels of drug products that are compounded \n                pursuant to section 503A of the Federal Food, Drug, and \n                Cosmetic Act.\n                    (E) Termination.--The advisory committee under this \n                subparagraph shall terminate upon the submission of the \n                recommendations under subparagraph (D).\n            (3) Database advisory committee.--\n                    (A) Establishment.--The Secretary of Health and \n                Human Services shall establish an advisory committee on \n                the database described in section 503A(g) of the \n                Federal Food, Drug, and Cosmetic Act, as added by \n                subsection (a), and shall consult such committee in the \n                development of the regulations under paragraph (1)(B).\n                    (B) Membership.--The advisory committee shall \n                include representatives of patients or consumers, \n                health care providers, compounding pharmacies, State \n                agencies that regulate compounding pharmacies, and \n                information technology experts.\n                    (C) Meetings.--The advisory committee shall hold an \n                initial meeting not later than 6 months after the date \n                of enactment of this Act.\n                    (D) Recommendations.--Not later than 12 months \n                after the date of enactment of this Act, the advisory \n                committee shall submit to the Secretary of Health and \n                Human Services recommendations on the regulations under \n                paragraph (1)(B).\n                    (E) Termination.--The advisory committee under this \n                subparagraph shall terminate upon the submission of the \n                recommendations under subparagraph (D).\n            (4) Permanent advisory committee on pharmacy compounding.--\n        The Secretary shall convene the Advisory Committee on Pharmacy \n        Compounding as appropriate to consider issues related to the \n        safety and availability of compounded drug products.\n\nSEC. 3. REPORTS AND STUDIES.\n\n    (a) Biannual Reports.--Not later than 6 months after the date of \nenactment of this Act, and at the end of each succeeding 6-month period \nthat ends before the 25th month after the date of enactment of this \nAct, the Secretary of Health and Human Services shall submit to the \nCongress a report on the status of the implementation of the \nrequirements of this Act, and the amendments made by this Act.\n    (b) Third-Party Accreditation.--Not later than 12 months after the \ndate of enactment of this Act, the Secretary shall submit to the \nCongress a report that contains--\n            (1) a review of the standards used by organizations that \n        provide accreditation to compounding pharmacies; and\n            (2) an evaluation of the effectiveness of such standards in \n        ensuring the production of safe and effective compounded drug \n        products.\n    (c) Structure of State Oversight.--Not later than 18 months after \nthe date of enactment of this Act, the Secretary shall submit to the \nCongress a report that contains--\n            (1) a review of the models used by States to structure \n        their oversight of pharmacies that compound drug products, \n        including the structure of the agency or office responsible for \n        oversight and its relationship with the industry that it \n        regulates; and\n            (2) consideration of how the structure and relationship of \n        State regulators may impact the development and enforcement of \n        regulations to ensure safe compounded drug products.\n    (d) GAO Report.--The Comptroller General of the United States shall \nreview--\n            (1) the extent to which Federal health care programs (as \n        such term is defined in section 1128B(f) of the Social Security \n        Act (42 U.S.C. 1320a-7b)) ensure that compounded drug products \n        which are paid for by such programs are compounded in \n        facilities that comply with the requirements of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);\n            (2) whether the reimbursement rates for compounded drug \n        products under such Federal health care programs are \n        appropriate, taking into consideration the cost of production \n        of such compounded drug products; and\n            (3) whether such Federal health care programs encourage the \n        use of compounded drug products in place of otherwise available \n        lawfully marketed drug products.\n\nSEC. 4. PROHIBITIONS AND PENALTIES.\n\n    (a) Prohibition of Violations of Section 503A.--Section 301(d) of \nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d)) is amended \nby inserting ``503A,'' before ``505,''.\n    (b) Penalties.--Section 303(b) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 333(b)) is amended by adding at the end the \nfollowing:\n            ``(8) Notwithstanding subsection (a), any person who \n        violates section 301(d) with respect to any compounded drug \n        product--\n                    ``(A) knowingly and intentionally to defraud or \n                mislead; or\n                    ``(B) with conscious or reckless disregard of a \n                risk of death or serious bodily injury,\n        shall be fined under title 18, United States Code, imprisoned \n        for not more than 10 years, or both.''."
}